Nexthera Capital LP bought a new position in shares of BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) in the 2nd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund bought 100,800 shares of the biotechnology company’s stock, valued at approximately $9,155,000. BioMarin Pharmaceutical makes up 4.0% of Nexthera Capital LP’s holdings, making the stock its 11th biggest position. Nexthera Capital LP owned about 0.06% of BioMarin Pharmaceutical as of its most recent filing with the Securities & Exchange Commission.

A number of other institutional investors have also bought and sold shares of BMRN. Jennison Associates LLC grew its position in BioMarin Pharmaceutical by 33.8% during the second quarter. Jennison Associates LLC now owns 13,242,773 shares of the biotechnology company’s stock worth $1,202,709,000 after buying an additional 3,348,168 shares in the last quarter. TIAA CREF Investment Management LLC grew its position in BioMarin Pharmaceutical by 63.7% during the second quarter. TIAA CREF Investment Management LLC now owns 2,251,011 shares of the biotechnology company’s stock worth $204,437,000 after buying an additional 875,686 shares in the last quarter. USS Investment Management Ltd grew its position in BioMarin Pharmaceutical by 214.7% during the second quarter. USS Investment Management Ltd now owns 1,089,933 shares of the biotechnology company’s stock worth $98,988,000 after buying an additional 743,599 shares in the last quarter. Vanguard Group Inc. grew its position in BioMarin Pharmaceutical by 4.7% during the second quarter. Vanguard Group Inc. now owns 14,345,027 shares of the biotechnology company’s stock worth $1,302,816,000 after buying an additional 642,623 shares in the last quarter. Finally, Manning & Napier Advisors LLC grew its position in BioMarin Pharmaceutical by 25.2% during the second quarter. Manning & Napier Advisors LLC now owns 2,118,486 shares of the biotechnology company’s stock worth $192,399,000 after buying an additional 426,016 shares in the last quarter. Institutional investors and hedge funds own 97.47% of the company’s stock.

BioMarin Pharmaceutical Inc. (BMRN) traded up 0.070% on Thursday, reaching $93.265. The company’s stock had a trading volume of 237,332 shares. The firm has a 50-day moving average of $89.07 and a 200-day moving average of $89.65. BioMarin Pharmaceutical Inc. has a one year low of $78.42 and a one year high of $100.51. The company’s market capitalization is $16.35 billion.

BioMarin Pharmaceutical (NASDAQ:BMRN) last announced its quarterly earnings data on Wednesday, August 2nd. The biotechnology company reported ($0.21) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.22) by $0.01. The business had revenue of $317.50 million during the quarter, compared to the consensus estimate of $311.41 million. BioMarin Pharmaceutical had a negative net margin of 15.54% and a negative return on equity of 5.77%. The firm’s quarterly revenue was up 5.8% compared to the same quarter last year. During the same quarter last year, the firm earned ($2.61) earnings per share. Analysts predict that BioMarin Pharmaceutical Inc. will post ($0.71) EPS for the current year.

In other news, EVP Jeffrey Robert Ajer sold 3,521 shares of BioMarin Pharmaceutical stock in a transaction that occurred on Friday, September 22nd. The shares were sold at an average price of $95.00, for a total transaction of $334,495.00. Following the completion of the sale, the executive vice president now owns 49,299 shares of the company’s stock, valued at $4,683,405. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director V Bryan Lawlis sold 3,750 shares of BioMarin Pharmaceutical stock in a transaction that occurred on Friday, September 15th. The shares were sold at an average price of $91.26, for a total transaction of $342,225.00. Following the sale, the director now directly owns 19,660 shares of the company’s stock, valued at approximately $1,794,171.60. The disclosure for this sale can be found here. In the last three months, insiders sold 40,686 shares of company stock valued at $3,736,318. 1.85% of the stock is owned by insiders.

Several research firms recently commented on BMRN. BidaskClub cut BioMarin Pharmaceutical from a “hold” rating to a “sell” rating in a research report on Monday, July 24th. Stifel Nicolaus reaffirmed a “buy” rating and set a $107.00 price target on shares of BioMarin Pharmaceutical in a research note on Friday, August 4th. Wedbush reaffirmed a “neutral” rating and set a $108.00 price target on shares of BioMarin Pharmaceutical in a research note on Monday, August 7th. Evercore ISI began coverage on BioMarin Pharmaceutical in a research note on Wednesday, August 16th. They set an “outperform” rating and a $100.00 price target for the company. Finally, Piper Jaffray Companies reaffirmed a “buy” rating and set a $113.00 price target on shares of BioMarin Pharmaceutical in a research note on Thursday, September 21st. Two investment analysts have rated the stock with a sell rating, ten have given a hold rating and fifteen have assigned a buy rating to the company’s stock. The company currently has a consensus rating of “Hold” and a consensus target price of $109.09.

ILLEGAL ACTIVITY NOTICE: This article was originally published by The Cerbat Gem and is the property of of The Cerbat Gem. If you are reading this article on another site, it was illegally stolen and republished in violation of U.S. and international trademark & copyright law. The legal version of this article can be viewed at https://www.thecerbatgem.com/2017/10/05/nexthera-capital-lp-invests-9-16-million-in-biomarin-pharmaceutical-inc-bmrn-stock.html.

BioMarin Pharmaceutical Profile

BioMarin Pharmaceutical Inc is a biotechnology company. The Company develops and commercializes pharmaceuticals for various diseases and medical conditions. As of December 31, 2016, the Company’s therapy portfolio consisted of five products, and multiple clinical and pre-clinical product candidates. Its commercial products include Aldurazyme (laronidase) for Mucopolysaccharidosis I (MPS I), Firdapse (amifampridine phosphate) for Lambert Eaton Myasthenic Syndrome (LEMS), Kuvan (sapropterin dihydrochloride) for phenylketonuria (PKU), Naglazyme (galsulfase) for Mucopolysaccharidosis VI (MPS VI) and Vimizim (elosulfase alpha) for Mucopolysaccharidosis IV Type A (MPS IV A).

Want to see what other hedge funds are holding BMRN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for BioMarin Pharmaceutical Inc. (NASDAQ:BMRN).

Institutional Ownership by Quarter for BioMarin Pharmaceutical (NASDAQ:BMRN)

Receive News & Stock Ratings for BioMarin Pharmaceutical Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioMarin Pharmaceutical Inc. and related stocks with our FREE daily email newsletter.